Evidence map›Paper›PMID 21949893›Full record

SynthesisPLoS neglected tropical diseases2011

Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review.

Charles H King, Stephanie K Olbrych, Margaret Soon, Mendel E Singer, Jen Carter, Daniel G Colley

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. SCORE Studies on the Impact of Drug Treatment on Morbidity due toThe American journal of tropical medicine and hygiene · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Drugs for treating urinary schistosomiasis.The Cochrane database of systematic reviews · 2014
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Direct measurement ofbioRxiv : the preprint server for biology · 2026
    Article
  19. Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Charles H KingCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. chk@cwru.edu
Stephanie K Olbrych
Margaret Soon
Mendel E Singer
Jen Carter
Daniel G Colley

Funding

Eco-epidemiology of Schistosomiasis, Malaria and Polyparasitism in Coastal KenyaR01TW008067 · FIC · CASE WESTERN RESERVE UNIVERSITY · PI KING, CHARLES HARDING, KITRON, URIEL DAN · 2007 to 2011
$2.4M
FIC NIH HHS R01 TW008067FIC NIH HHS (TW008067
6 · The paper itself

Abstract

backgroundControversy persists about the optimal approach to drug-based control of schistosomiasis in high-risk communities. In a systematic review of published studies, we examined evidence for incremental benefits from repeated praziquantel dosing, given 2 to 8 weeks after an initial dose, in Schistosoma-endemic areas of Africa. METHODOLOGY/PRINCIPAL

findingsWe performed systematic searches of electronic databases PubMed and EMBASE for relevant data using search terms 'schistosomiasis', 'dosing' and 'praziquantel' and hand searches of personal collections and bibliographies of recovered articles. In 10 reports meeting study criteria, improvements in parasitological treatment outcomes after two doses of praziquantel were greater for S. mansoni infection than for S. haematobium infection. Observed cure rates (positive to negative conversion in egg detection assays) were, for S. mansoni, 69-91% cure after two doses vs. 42-79% after one dose and, for S. haematobium, 46-99% cure after two doses vs. 37-93% after a single dose. Treatment benefits in terms of reduction in intensity (mean egg count) were also different for the two species-for S. mansoni, the 2-dose regimen yielded an weighted average 89% reduction in standardized egg counts compared to a 83% reduction after one dose; for S. haematobium, two doses gave a 93% reduction compared to a 94% reduction with a single dose. Cost-effectiveness analysis was performed based on Markov life path modeling. CONCLUSIONS/SIGNIFICANCE: Although schedules for repeated treatment with praziquantel require greater inputs in terms of direct costs and community participation, there are incremental benefits to this approach at an estimated cost of $153 (S. mansoni)-$211 (S. haematobium) per additional lifetime QALY gained by double treatment in school-based programs. More rapid reduction of infection-related disease may improve program adherence, and if, as an externality of the program, transmission can be reduced through more effective coverage, significant additional benefits are expected to accrue in the targeted communities.

Indexed as

AdolescentAdultAfricaAnimalsAnthelminticsChildChild, PreschoolHumansMiddle AgedPraziquantelQuality of LifeSchistosoma haematobiumSchistosoma mansoniSchistosomiasisTime FactorsTreatment OutcomeAnthelminticsPraziquantel

Identifiers

PMID21949893
PMCPMC3176745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.